Klima A, Bergmann I, Szepesi S
HNO-Universitätsklinik Frankfurt, Main, Germany.
J Laryngol Otol. 1992 Mar;106(3):234-7. doi: 10.1017/s0022215100119140.
We treated 114 patients with advanced inoperable head and neck cancer with a combined-modality protocol that included two cycles of chemotherapy followed by radiotherapy or three chemotherapy and in 18 patients with a radiosensitizing agent. At the beginning of the treatment all but one patient presented with a stage IV cancer. With a follow-up of 42-58 months, four patients are alive (three from the radiosensitizing group and one of the chemotherapy group). Complete response after the radiosensitizing agent correlated with superior prolonged disease-free survival in comparison to complete responses after chemotherapy at the level of p less than 0.009.
我们采用一种综合治疗方案治疗了114例无法手术的晚期头颈癌患者,该方案包括两个周期的化疗,随后进行放疗,或者三个周期的化疗,并对18例患者使用了放射增敏剂。治疗开始时,除1例患者外,所有患者均为IV期癌症。随访42 - 58个月后,4例患者存活(放射增敏组3例,化疗组1例)。与化疗后的完全缓解相比,放射增敏剂后的完全缓解在p值小于0.009的水平上与更长的无病生存期相关。